Long acting GLP-1 receptor agonist (injectable)
Taspoglutide injection
TASP_SC
Doses in this pooled treatment
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.07 (-1.41 to -0.73) | 0.71 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.25 (-1.37 to 0.95) | 0.50 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -1.50 (-7.24 to 4.88) | 0.57 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -1.23 (-2.78 to 0.27) | 0.70 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.11 (0.00 to 3.89) | 0.64 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.36 (0.70 to 2.74) | 0.55 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -2.48 (-5.43 to 0.52) | 0.62 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 0.01 (-4.91 to 5.75) | 0.55 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.91 (0.59 to 1.40) | 0.56 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 3.62 (1.76 to 7.47) | 0.20 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 5.35 (3.38 to 8.53) | 0.16 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 7.91 (4.39 to 14.34) | 0.13 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.81 (1.25 to 2.71) | 0.37 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.66 (1.86 to 7.46) | 0.15 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 2.76 (0.49 to 14.91) | 0.35 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.31 (0.03 to 3.43) | 0.62 |
Trials
- NCT00754988A Multicenter, Randomized, Double-dummy, Placebo and Active-controlled Study to Assess the Safety, Tolerability and Effect of Taspoglutide on Glycemic Control Compared to Sitagliptin and Placebo in Patients With Type II Diabetes Mellitus Inadequately Controlled With Metformin.2008 · 666 randomized · 156 weeks
- NCT00717457Randomized, Active Controlled, Open Label Study to Compare Taspoglutide vs Exenatide as add-on Treatment to Metformin and/or Thiazolidinediones in Patients With Type 2 Diabetes Mellitus2008 · 1,189 randomized · 52 weeks
- NCT00744926A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Effect of Taspoglutide Compared to Placebo, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise2008 · 373 randomized · 24 weeks
- NCT00460941A Double-blind, Placebo-controlled Titration Study to Investigate the Tolerability, Safety and Pharmacodynamic Profile of a GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin.2007 · 133 randomized · 8 weeks
- NCT00423501A Double Blind, Placebo-controlled, Dose-ranging Study to Investigate the Effect on Glycemic Control, Safety, Pharmacokinetics and Pharmacodynamics of GLP-1 in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin.2007 · 306 randomized · 8 weeks